Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspective

K. de Joode; D. W. Dumoulin; V. Engelen; H. J. Bloemendal; M. Verheij; H. W. M. van Laarhoven; I. H. Dingemans; A. C. Dingemans; A. A. M. van der Veldt

doi:10.1016/j.ejca.2020.06.019

Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspective

K. de Joode, D. W. Dumoulin, V. Engelen, H. J. Bloemendal, M. Verheij, H. W. M. van Laarhoven, I. H. Dingemans, A. C. Dingemans, A. A. M. van der Veldt^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, has inevitable consequences for medical care of patients without COVID-19. To assess the impact of this pandemic on oncological care, a nationwide survey was conducted among patients with cancer in the Netherlands.

Methods: The patients' perspective on oncological care was investigated using an online survey between March 29th 2020 and April 18th 2020. The survey consisted of 20 questions on four topics: patients' characteristics, contact with the hospital, consequences of the COVID-19 pandemic and concerns about COVID-19.

Results: Five thousand three hundred two patients with cancer completed this nationwide survey. Overall, 30% of patients reported consequences for their oncological treatment or follow-up. In the majority of cases, this resulted in conversion from hospital visit to consultation by phone or video. The most frequently adjusted treatments were chemotherapy (30%) and immunotherapy (32%). Among patients with delay and discontinuation of treatment, 55% and 63% of patients, respectively, were (very) concerned about these consequences of the COVID-19 pandemic. Consequences were independent of regional differences in COVID-19 incidence. However, patients in regions with high COVID-19 incidence were significantly more concerned.

Conclusion: This is the first study investigating perspectives of patients with cancer during the COVID-19 pandemic. The study demonstrates the significant impact of the COVID-19 crisis on oncological care, indicating the need for psycho-oncological support during this pandemic. (C) 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Original language	English
Pages (from-to)	132-139
Number of pages	8
Journal	European Journal of Cancer
Volume	136
DOIs	https://doi.org/10.1016/j.ejca.2020.06.019
Publication status	Published - Sept 2020

Keywords

COVID-19
Cancer
Coronavirus
LUNG-CANCER
Pandemic
Patients' perspective

Access to Document

10.1016/j.ejca.2020.06.019Licence: CC BY

Cite this

@article{5b501e42524e4e0cb2899e60677e29e6,

title = "Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspective",

abstract = "Background: The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, has inevitable consequences for medical care of patients without COVID-19. To assess the impact of this pandemic on oncological care, a nationwide survey was conducted among patients with cancer in the Netherlands.Methods: The patients' perspective on oncological care was investigated using an online survey between March 29th 2020 and April 18th 2020. The survey consisted of 20 questions on four topics: patients' characteristics, contact with the hospital, consequences of the COVID-19 pandemic and concerns about COVID-19.Results: Five thousand three hundred two patients with cancer completed this nationwide survey. Overall, 30% of patients reported consequences for their oncological treatment or follow-up. In the majority of cases, this resulted in conversion from hospital visit to consultation by phone or video. The most frequently adjusted treatments were chemotherapy (30%) and immunotherapy (32%). Among patients with delay and discontinuation of treatment, 55% and 63% of patients, respectively, were (very) concerned about these consequences of the COVID-19 pandemic. Consequences were independent of regional differences in COVID-19 incidence. However, patients in regions with high COVID-19 incidence were significantly more concerned.Conclusion: This is the first study investigating perspectives of patients with cancer during the COVID-19 pandemic. The study demonstrates the significant impact of the COVID-19 crisis on oncological care, indicating the need for psycho-oncological support during this pandemic. (C) 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).",

keywords = "COVID-19, Cancer, Coronavirus, LUNG-CANCER, Pandemic, Patients' perspective",

author = "{de Joode}, K. and Dumoulin, {D. W.} and V. Engelen and Bloemendal, {H. J.} and M. Verheij and {van Laarhoven}, {H. W. M.} and Dingemans, {I. H.} and Dingemans, {A. C.} and {van der Veldt}, {A. A. M.}",

note = "Funding Information: D.W.D. reports receiving personal fees and speaker fee from MSD , Roche , AstaZeneca , BMS , Novartis and Pfizer , outside the submitted work. A.C.D. reports receiving personal fees from Roche , PharmaMar , Boehringer Ingelheim , Novartis , Takeda , Pfizer and Eli Lilly ; grants from BMS and Amgen and non-financial support from Abbvie,grants fees outside the submitted work; Funding Information: D.W.D. reports receiving personal fees and speaker fee from MSD, Roche, AstaZeneca, BMS, Novartis and Pfizer, outside the submitted work. A.C.D. reports receiving personal fees from Roche, PharmaMar, Boehringer Ingelheim, Novartis, Takeda, Pfizer and Eli Lilly; grants from BMS and Amgen and non-financial support from Abbvie,grants fees outside the submitted work;A.A.M.v.d.V. reports receiving other grants from BMS, MSD, Merck, Pfizer, Ipsen, Eisai, Pierre Fabre, Roche, Novartis and Sanofi, outside the submitted work. All other authors report no conflict of interest. Funding Information: A.A.M.v.d.V. reports receiving other grants from BMS , MSD , Merck , Pfizer , Ipsen , Eisai , Pierre Fabre , Roche , Novartis and Sanofi , outside the submitted work. All other authors report no conflict of interest. Publisher Copyright: {\textcopyright} 2020 The Author(s)",

year = "2020",

month = sep,

doi = "10.1016/j.ejca.2020.06.019",

language = "English",

volume = "136",

pages = "132--139",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "ELSEVIER SCI LTD",

}

TY - JOUR

T1 - Impact of the coronavirus disease 2019 pandemic on cancer treatment

T2 - the patients' perspective

AU - de Joode, K.

AU - Dumoulin, D. W.

AU - Engelen, V.

AU - Bloemendal, H. J.

AU - Verheij, M.

AU - van Laarhoven, H. W. M.

AU - Dingemans, I. H.

AU - Dingemans, A. C.

AU - van der Veldt, A. A. M.

N1 - Funding Information: D.W.D. reports receiving personal fees and speaker fee from MSD , Roche , AstaZeneca , BMS , Novartis and Pfizer , outside the submitted work. A.C.D. reports receiving personal fees from Roche , PharmaMar , Boehringer Ingelheim , Novartis , Takeda , Pfizer and Eli Lilly ; grants from BMS and Amgen and non-financial support from Abbvie,grants fees outside the submitted work; Funding Information: D.W.D. reports receiving personal fees and speaker fee from MSD, Roche, AstaZeneca, BMS, Novartis and Pfizer, outside the submitted work. A.C.D. reports receiving personal fees from Roche, PharmaMar, Boehringer Ingelheim, Novartis, Takeda, Pfizer and Eli Lilly; grants from BMS and Amgen and non-financial support from Abbvie,grants fees outside the submitted work;A.A.M.v.d.V. reports receiving other grants from BMS, MSD, Merck, Pfizer, Ipsen, Eisai, Pierre Fabre, Roche, Novartis and Sanofi, outside the submitted work. All other authors report no conflict of interest. Funding Information: A.A.M.v.d.V. reports receiving other grants from BMS , MSD , Merck , Pfizer , Ipsen , Eisai , Pierre Fabre , Roche , Novartis and Sanofi , outside the submitted work. All other authors report no conflict of interest. Publisher Copyright: © 2020 The Author(s)

PY - 2020/9

Y1 - 2020/9

N2 - Background: The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, has inevitable consequences for medical care of patients without COVID-19. To assess the impact of this pandemic on oncological care, a nationwide survey was conducted among patients with cancer in the Netherlands.Methods: The patients' perspective on oncological care was investigated using an online survey between March 29th 2020 and April 18th 2020. The survey consisted of 20 questions on four topics: patients' characteristics, contact with the hospital, consequences of the COVID-19 pandemic and concerns about COVID-19.Results: Five thousand three hundred two patients with cancer completed this nationwide survey. Overall, 30% of patients reported consequences for their oncological treatment or follow-up. In the majority of cases, this resulted in conversion from hospital visit to consultation by phone or video. The most frequently adjusted treatments were chemotherapy (30%) and immunotherapy (32%). Among patients with delay and discontinuation of treatment, 55% and 63% of patients, respectively, were (very) concerned about these consequences of the COVID-19 pandemic. Consequences were independent of regional differences in COVID-19 incidence. However, patients in regions with high COVID-19 incidence were significantly more concerned.Conclusion: This is the first study investigating perspectives of patients with cancer during the COVID-19 pandemic. The study demonstrates the significant impact of the COVID-19 crisis on oncological care, indicating the need for psycho-oncological support during this pandemic. (C) 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

AB - Background: The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, has inevitable consequences for medical care of patients without COVID-19. To assess the impact of this pandemic on oncological care, a nationwide survey was conducted among patients with cancer in the Netherlands.Methods: The patients' perspective on oncological care was investigated using an online survey between March 29th 2020 and April 18th 2020. The survey consisted of 20 questions on four topics: patients' characteristics, contact with the hospital, consequences of the COVID-19 pandemic and concerns about COVID-19.Results: Five thousand three hundred two patients with cancer completed this nationwide survey. Overall, 30% of patients reported consequences for their oncological treatment or follow-up. In the majority of cases, this resulted in conversion from hospital visit to consultation by phone or video. The most frequently adjusted treatments were chemotherapy (30%) and immunotherapy (32%). Among patients with delay and discontinuation of treatment, 55% and 63% of patients, respectively, were (very) concerned about these consequences of the COVID-19 pandemic. Consequences were independent of regional differences in COVID-19 incidence. However, patients in regions with high COVID-19 incidence were significantly more concerned.Conclusion: This is the first study investigating perspectives of patients with cancer during the COVID-19 pandemic. The study demonstrates the significant impact of the COVID-19 crisis on oncological care, indicating the need for psycho-oncological support during this pandemic. (C) 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

KW - COVID-19

KW - Cancer

KW - Coronavirus

KW - LUNG-CANCER

KW - Pandemic

KW - Patients' perspective

U2 - 10.1016/j.ejca.2020.06.019

DO - 10.1016/j.ejca.2020.06.019

M3 - Article

C2 - 32683273

SN - 0959-8049

VL - 136

SP - 132

EP - 139

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspective

Abstract

Keywords

Access to Document

Fingerprint

Cite this